ALNY logo

Alnylam Pharmaceuticals Inc (ALNY)

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for...

NASDAQHealthcareBiotechnologyUSA

公司簡介

股票程式碼
ALNY
ISIN程式碼
US02043Q1076
貨幣
US Dollar (USD)
IPO日期
2004-05-28

聯絡資訊

公司地址
675 West Kendall Street, Cambridge, MA, United States, 02142
聯絡電話
617 551 8200
公司網站
https://www.alnylam.com
財年結束
December

財務亮點

市值
$999,999.99
毛利潤(TTM)
$999,999.99
資產回報率(TTM)
12.34%
EBITDA
$999,999.99
收入(TTM)
$999,999.99